Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Database management of quality of life cancer literature,

Go back to Resources

Database management of quality of life cancer literature,

Authors:

Location:

Go back to Resources

Conversion to tacrolimus to ameliorate cyclosporine toxicities.

Go back to Resources

Conversion to tacrolimus to ameliorate cyclosporine toxicities.

Authors:

Go back to Resources

Comparison of TMJ scale and RDC-axis II for psychological assessment of TMD.

Go back to Resources

Comparison of TMJ scale and RDC-axis II for psychological assessment of TMD.

Authors:

Location:

Go back to Resources

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis,

Go back to Resources

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Clinical trials referral resource. Trials of topotecan,

Go back to Resources

Clinical trials referral resource. Trials of topotecan,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Clinical trials referral resource. Prostate cancer II,

Go back to Resources

Clinical trials referral resource. Prostate cancer II,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Clinical trials referral resource. Myelodysplastic syndromes,

Go back to Resources

Clinical trials referral resource. Myelodysplastic syndromes,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Clinical trials referral resource. Mycosis fungoides/Sezary syndrome,

Go back to Resources

Clinical trials referral resource. Mycosis fungoides/Sezary syndrome,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Clinical Trials Referral Resource. Lung cancer.

Go back to Resources

Clinical Trials Referral Resource. Lung cancer.

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Progress in HIV-1 Vaccine Development

Go back to Resources

Progress in HIV-1 Vaccine Development

Authors:

Location:

URL:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 104
  • Page 105
  • Page 106
  • Page 107
  • Current page 108
  • Page 109
  • Page 110
  • Page 111
  • Page 112
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification